Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis?

The study of the ovarian proteomic profile represents a new frontier in ovarian cancer research, since this approach is able to enlighten the wide variety of post-translational events (such as glycosylation and phosphorylation). Due to the possibility of analyzing thousands of proteins, which could be simultaneously altered, comparative proteomics represent a promising model of possible biomarker discovery for ovarian cancer detection and monitoring. Moreover, defining signaling pathways in ovarian cancer cells through proteomic analysis offers the opportunity to design novel drugs and to optimize the use of molecularly targeted agents against crucial and biologically active pathways. Proteomic techniques provide more information about different histological types of ovarian cancer, cell growth and progression, genes related to tumor microenvironment and specific molecular targets predictive of response to chemotherapy than sequencing or microarrays. Estimates of specificity with proteomics are less consistent, but suggest a new role for combinations of biomarkers in early ovarian cancer diagnosis, such as the OVA1 test. Finally, the definition of the proteomic profiles in ovarian cancer would be accurate and effective in identifying which pathways are differentially altered, defining the most effective therapeutic regimen and eventually improving health outcomes.

[1]  Adelina Rogowska-Wrzesinska,et al.  2D gels still have a niche in proteomics. , 2013, Journal of proteomics.

[2]  Uros Kuzmanov,et al.  Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids , 2013, Clinical chemistry and laboratory medicine.

[3]  K. Taskén,et al.  Cell signalling analyses in the functional genomics era. , 2013, New biotechnology.

[4]  D. Hashad,et al.  Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? , 2013, Archives of Gynecology and Obstetrics.

[5]  H. Møller,et al.  Investigation of human cationic antimicrobial protein-18 (hCAP-18), lactoferrin and CD163 as potential biomarkers for ovarian cancer , 2013, Journal of Ovarian Research.

[6]  A. Tessitore,et al.  Serum Biomarkers Identification by Mass Spectrometry in High-Mortality Tumors , 2013, International journal of proteomics.

[7]  A. Goy,et al.  Early Detection Biomarkers for Ovarian Cancer , 2012, Journal of oncology.

[8]  A. Heck,et al.  Next-generation proteomics: towards an integrative view of proteome dynamics , 2012, Nature Reviews Genetics.

[9]  Y. Mechref,et al.  Defining putative glycan cancer biomarkers by MS. , 2012, Bioanalysis.

[10]  I. Fournier,et al.  Targeted mass spectrometry imaging: specific targeting mass spectrometry imaging technologies from history to perspective. , 2012, Progress in histochemistry and cytochemistry.

[11]  E. Ratner,et al.  Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer , 2012, Current opinion in oncology.

[12]  R. Philip,et al.  Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics , 2012, Clinical Proteomics.

[13]  Yehia Mechref,et al.  Identifying cancer biomarkers by mass spectrometry‐based glycomics , 2012, Electrophoresis.

[14]  I. Fournier,et al.  Ovarian cancer molecular pathology , 2012, Cancer and Metastasis Reviews.

[15]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[16]  Kaitai Zhang,et al.  The ovarian cancer‐derived secretory/releasing proteome: A repertoire of tumor markers , 2012, Proteomics.

[17]  I. Căruntu,et al.  Ovarian cancer: insights into genetics and pathogeny. , 2012, Histology and histopathology.

[18]  R. Jankowitz,et al.  A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer , 2012, Familial Cancer.

[19]  H. Rodriguez,et al.  Mass spectrometry‐based targeted quantitative proteomics: Achieving sensitive and reproducible detection of proteins , 2012, Proteomics.

[20]  J. Fíla,et al.  Enrichment techniques employed in phosphoproteomics , 2011, Amino Acids.

[21]  Bei Zhang,et al.  An overview of biomarkers for the ovarian cancer diagnosis. , 2011, European journal of obstetrics, gynecology, and reproductive biology.

[22]  M. Federico,et al.  Protein expression patterns associated with advanced stage ovarian cancer , 2011, Electrophoresis.

[23]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[24]  T. Walsh,et al.  Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. , 2011, Cancer research.

[25]  Sudhir Srivastava,et al.  A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer , 2011, Cancer Prevention Research.

[26]  D Timmerman,et al.  HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm , 2011, British Journal of Cancer.

[27]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[28]  Akhilesh Pandey,et al.  Phosphoproteomics in cancer , 2010, Molecular oncology.

[29]  D. Chan,et al.  The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[30]  E. Kohn,et al.  Proteomics as a guiding tool for more effective personalized therapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  E. Kohn,et al.  Proteomics and ovarian cancer: integrating proteomics information into clinical care. , 2010, Journal of proteomics.

[32]  A. Ashworth,et al.  Making the best of PARP inhibitors in ovarian cancer , 2010, Nature Reviews Clinical Oncology.

[33]  B. Kuster,et al.  Proteomics: a pragmatic perspective , 2010, Nature Biotechnology.

[34]  W. Holzgreve,et al.  Proteomics and biomarkers for ovarian cancer diagnosis. , 2010, Annals of clinical and laboratory science.

[35]  L. Wells,et al.  Identification of candidate biomarkers with cancer‐specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis , 2010, Proteomics.

[36]  E. Fung,et al.  A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. , 2010, Clinical chemistry.

[37]  O. Johannsson,et al.  Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes , 2009, Breast Cancer Research.

[38]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[39]  D. Ankerst,et al.  Afamin and Apolipoprotein A-IV: Novel Protein Markers for Ovarian Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[40]  Yuan Zhou,et al.  Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. , 2009, Cancer letters.

[41]  G. Mor,et al.  Development and Validation of a Protein -based Signature for the Detection of Ovarian Cancer Ovarian Cancer Early Detection Leptin Prolactin Osteopontin Macrophage Inhibitory Factor (mif) Insulin-like Growth Factor-ii (igf-ii) Multiplex , 2022 .

[42]  T. Yip,et al.  Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology , 2009, Acta obstetricia et gynecologica Scandinavica.

[43]  Feng Su,et al.  The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? , 2008, American journal of obstetrics and gynecology.

[44]  A. Ardekani,et al.  Application of genomic and proteomic technologies to early detection of cancer. , 2008, Archives of Iranian medicine.

[45]  Ie-Ming Shih,et al.  Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[46]  G. Hall,et al.  Proteomic Profiling Identifies Afamin as a Potential Biomarker for Ovarian Cancer , 2007, Clinical Cancer Research.

[47]  J. Kelley,et al.  Strategies for ovarian cancer prevention. , 2007, Obstetrics and gynecology clinics of North America.

[48]  S. Steinberg,et al.  A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer , 2007, Cancer.

[49]  Liam A McDonnell,et al.  Imaging mass spectrometry. , 2007, Mass spectrometry reviews.

[50]  S. Steinberg,et al.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer , 2007, Cancer.

[51]  Paul Workman,et al.  Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. , 2007, Cancer research.

[52]  C. Salustri,et al.  Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients , 2007 .

[53]  H. An,et al.  Comparative proteomics of ovarian epithelial tumors. , 2006, Journal of proteome research.

[54]  T. Walsh,et al.  Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. , 2006, JAMA.

[55]  Gordon B Mills,et al.  Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon , 2005, Clinical Cancer Research.

[56]  Hongyu Zhao,et al.  Serum protein markers for early detection of ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Wenjun Cheng,et al.  Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract , 2005, Nature Medicine.

[58]  Walter Kolch,et al.  The molecular make-up of a tumour: proteomics in cancer research. , 2005, Clinical science.

[59]  William L. Bigbee,et al.  Multiplexed Immunobead-Based Cytokine Profiling for Early Detection of Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[60]  Yiling Lu,et al.  Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma* , 2005, Molecular & Cellular Proteomics.

[61]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[62]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[63]  A. Berchuck,et al.  Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  E. Fung,et al.  Proteomic approaches to tumor marker discovery. , 2002, Archives of pathology & laboratory medicine.

[65]  J. Mecklin,et al.  The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. , 2001, Gynecologic oncology.

[66]  T. Rebbeck,et al.  BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. , 1998, American journal of obstetrics and gynecology.

[67]  J. Mecklin,et al.  The International Collaborative Group on HNPCC. , 1994, Anticancer research.

[68]  R. Kimmig,et al.  Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. , 2013, Anticancer research.

[69]  Ruth M Pfeiffer,et al.  Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial , 2012, Cancer.

[70]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[71]  G. Lippi,et al.  HE4 in ovarian cancer: from discovery to clinical application. , 2011, Advances in clinical chemistry.

[72]  J. Dungan.  HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm , 2011 .

[73]  Steven J Skates,et al.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. , 2009, Gynecologic oncology.

[74]  T. Conrads,et al.  Serum proteomics using mass spectrometry. , 2009, Methods in molecular biology.

[75]  G. Szász.  γ-Glutamyltranspeptidase-Aktivität im Urin , 1970 .

[76]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.